The ongoing P-IIb trial of XW003 (1.2/1.8/2.4mg, qw) vs liraglutide (3.0mg, qd for 26wks.) in 206 patients with obesity at 9 sites in Australia & New Zealand. The study is expected to be completed at the end of 2022 with anticipated results in 2023
The results showed that patients treated with XW003 (2.4mg, qw) achieved a mean body weight reduction from baseline of 11.1% (10.9 kg) vs 7.9% (8.1 kg), ≥5% & ≥10% body weight loss from baseline (88.5% for 2.4mg vs 70.4%) & (57.7% vs 33.3%), favorable trends were also observed for other efficacy parameters
The therapy was safe & well tolerated, the AE profile was consistent with other GLP-1 drugs, and patients reporting any AE during the treatment period were similar among 4 treatment groups after 18wks.
Ref: PR Newsswire | Image: Sciwind
